This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
by Zacks Equity Research
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw AbbVie (ABBV) settling at $169.91, representing a +1.05% change from its previous close.
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?
by Kinjel Shah
Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Zacks Analyst Blog Highlights Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian
by Zacks Equity Research
Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian are included in this Analyst Blog.
Top Stock Reports for Novo Nordisk, AbbVie & AstraZeneca
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and AstraZeneca PLC (AZN), as well as two micro-cap stocks, Air T, Inc. (AIRT) and United-Guardian, Inc. (UG).
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
by Zacks Equity Research
Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Company News for Jul 3, 2024
by Zacks Equity Research
Companies in The News Are: TSLA, AAPL, IQ, ABBV
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
by Zacks Equity Research
AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
by Zacks Equity Research
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
by Kinjel Shah
FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
by Zacks Equity Research
AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
by Zacks Equity Research
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
by Zacks Equity Research
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for COWZ
AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection
by Zacks Equity Research
AbbVie (ABBV) issues the second CRL for Parkinson's disease medicine, ABBV-951, based on some observations on inspection of one of its third-party manufacturing facilities.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
AbbVie (ABBV) reachead $170.75 at the closing of the latest trading day, reflecting a -1.15% change compared to its last close.
Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for COWZ
Here's Why You Should Consider Buying Alvotech (ALVO) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.